Drugs / 89Zr-DFO-YS5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07664397 | Aug 2026 → Sep 2029 expected | carcinoma, nerve sheath neoplasm, urinary bladder cancer | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05245006 | Mar 2022 → Jul 2027 expected | castration-resistant prostate carcinoma | University of California, San Francisco | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [89Zr]DFO-YS5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07664397 ↗ |
| Modality | Diagnostic / imaging agent | “89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy” NCT05245006 ↗ |
| Route | Intravenous | “3 mCi will be administered intravenously” NCT05245006 ↗ |
| Target | CD46 | “feasibility of targeting cluster of differentiation 46 (CD46)” NCT05245006 ↗ |